INSIGHTEC Closes $150 Million Series E Financing

Haifa, Israel and Miami (ots/PRNewswire) -

INSIGHTEC, a commercial-stage medical technology company
revolutionizing surgery with incisionless MRI-guided focused
ultrasound (MRgFUS) announced today the closing of a $150 million
Series E private equity investment round. Koch Disruptive
Technologies (KDT), a subsidiary of Koch Industries, focused on
finding and funding innovative and emerging companies, led the round
with a $100 million investment.

INSIGHTEC plans to use the proceeds from the financing to support
marketing and commercialization for its approved safe and
non-invasive treatments, including Exablate® Neuro for essential
tremor (ET), and for continuing research and development towards
addressing other brain indications including Parkinson's disease,
Alzheimer's disease, and cancer.

"INSIGHTEC is committed to driving global adoption of our existing
focused ultrasound treatments, while leading ground-breaking research
to apply our proprietary technology in novel ways," said Maurice R.
Ferré, MD, INSIGHTEC's Chief Executive Officer and Chairman of the
Board. "With this substantial investment, we plan to ultimately
leverage our incisionless solutions to positively transform the lives
of millions of patients."

INSIGHTEC's Exablate Neuro is the first focused ultrasound device
approved by the FDA to safely and non-invasively treat ET in patients
that have not responded to medication. Neurosurgeons use the
INSIGHTEC device in an incisionless procedure that delivers focused
ultrasound beams to the target deep in the brain. Where the beams
converge, the temperature rises causing thermal ablation, monitored
in real-time with MR imaging. Many patients who have undergone the
non-invasive treatment report immediate and lasting relief from their
tremor and improved quality of life. There are currently more than
forty medical centers around the world treating ET patients and
developing future applications with incisionless MRgFUS.

KDT joins existing INSIGHTEC investors including Elbit Imaging, York
Capital, Exigent Capital Group, GE Healthcare, GEOC, and Meditech
Advisors.

About INSIGHTEC

INSIGHTEC is the world leader and innovator of MRI-guided Focused
Ultrasound. The company's non-invasive therapy platforms, Exablate
and Exablate Neuro, are proven technology based on sound clinical
evidence for treating essential tremor, painful bone metastases and
uterine fibroids. The company is dedicated to improving patient lives
by collaborating with physicians, medical institutions, academic
researchers and regulatory bodies around the world. INSIGHTEC is
headquartered in Haifa, Israel, and Miami, with offices in Dallas,
Tokyo and Shanghai.

"Exablate," as well as the "INSIGHTEC" logo, whether standing
alone or in connection with the word "INSIGHTEC" are protected
trademarks of INSIGHTEC.

For more information, please visit: http://www.insightec.com.

MEDIA CONTACT:

MICHELLE BARRY

Red Lorry Yellow Lorry for INSIGHTEC

insightec@rlyl.com

+1-(857)-217-2886

ots Originaltext: InSightec
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: InSightec, übermittelt durch news aktuell